



1fw
DOCKET NO.: B0801.70256US01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Pier et al.
Serial No.: 10/712,391
Confirmation No.: 8225
Filed: November 12, 2003
For: METHODS AND PRODUCTS FOR TREATING STAPHYLOCOCCAL
INFECTIONS
Examiner: Not Yet Assigned
Art Unit: 1645

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 23rd day of May, 2005.

Kristin J. Ketelhut

MAIL STOP AMENDMENT

Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following documents:

- Information Disclosure Statement
- PTO Form 1449 with cited references
- Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 646-8000, Boston, Massachusetts.

A check is not enclosed. If a fee is required, the Commissioner is hereby authorized to charge Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,
Pier et al., Applicant

By:

Maria A. Trevisan, Reg. No.: 48,207
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
Telephone: (617) 646-8000

Docket No.: B0801.70256US01
Date: May 23, 2005
xNDDx




DOCKET NO.: B0801.70256US01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Pier et al.
Serial No.: 10/712,391
Confirmation No.: 8225
Filed: November 12, 2003
For: METHODS AND PRODUCTS FOR TREATING
STAPHYLOCOCCAL INFECTIONS
Examiner: Not Yet Assigned
Art Unit: 1645

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 23rd day of May, 2005.


Kristin J. Ketelhut

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed before the mailing date of a first Office Action on the merits in the above-identified case.

No fee or certification is required.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application.

The Applicant would like to bring to the Examiner's attention the following co-pending applications that may contain subject matter related to this application:

<u>Docket No.</u>	<u>Serial No.</u>	<u>Filing Date</u>	<u>Inventor(s)</u>
B0801.70300US01	11/111,688	April 21, 2005	Pier et al.

*a copy of this reference is not provided as the Office hereby waives the requirement under 37 CFR 1.98(a)(2)(iii) for submitting a copy of each cited U.S. patent application filed after June 30, 2003 and for applications filed before June 30, 2003, or that entered the national stage before June 30, 2003, if they are scanned to Image File Wrapper system and are available on Private PAIR.

The Applicant would like to bring to the Examiner's attention the enclosed search report from a corresponding International or Foreign National Application.

<u>Docket No.</u>	<u>Serial No.</u>	<u>Mailing Date</u>	<u>Type of Communication(s)</u>
B0801.70256WO00	PCT/US03/36371	April 13, 2005	Invitation to Pay Additional Fees

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,
Pier et al., Applicant


By:



Maria A. Trevisan, Reg. No. 48,207
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
Telephone: (617) 646-8000

Docket No.: B0801.70256US01
Date: May 23, 2005
xNDDx

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICATION NO.: 10/712,391	ATTY. DOCKET NO.: B0801.70256US01
		FILING DATE: November 12, 2003	CONFIRMATION NO.: 8225
		APPLICANT: Pier et al.	
		GROUP ART UNIT: 1645	EXAMINER: Not Yet Assigned
Sheet	1	of	7



U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	A1	4,197,290		Yoshida	04-08-1980
	A2	4,285,936		Pier et al.	08-25-1981
	A3	4,443,549		Sadowski	04-17-1984
	A4	4,578,458		Pier	03-25-1986
	A5	4,652,448		Sadowski	03-24-1987
	A6	4,786,592		Deal et al.	11-22-1988
	A7	4,789,735		Frank et al.	12-06-1988
	A8	4,795,803		Lindberg et al.	01-03-1989
	A9	4,830,852		Marburg et al.	05-16-1989
	A10	4,859,449		Mattes	08-22-1989
	A11	4,879,272		Shimoda et al.	11-07-1989
	A12	4,902,616		Fournier et al.	02-20-1990
	A13	5,055,455		Pier	10-08-1991
	A14	5,362,754		Raad et al.	11-08-1994
	A15	5,366,505		Farber	11-22-1994
	A16	5,571,511		Fischer	11-05-1996
	A17	5,589,591		Lewis	12-31-1996
	A18	5,688,516		Raad et al.	11-18-1997
	A19	5,718,694		Rupp	02-17-1998
	A20	5,830,539		Yan et al.	11-03-1998
	A21	5,866,140		Fattom et al.	02-02-1999
	A22	5,980,910		Pier	11-09-1999
	A23	5,989,542		Pier et al.	11-23-1999
	A24	6,245,735	B1	Pier	06-12-2001
	A25	6,399,066	B1	Pier	06-04-2002
	A26	6,743,431	B2	Pier	06-01-2004
	A27	2002-0119166	A1	Pier et al.	08-29-2002
	A28	2003-0124631	A1	Pier et al.	07-03-2003
	A29	2004-0091494	A1	Pier et al.	05-13-2004
	A30	2004-0175731	A1	Pier et al.	09-09-2004
	A31	2005-0025775	A1	Pier et al.	02-03-2005

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
	B1	EP	0 302 781	A1	Institut Pasteur	02-08-1989	Y- Abstr.

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/712,391		ATTY. DOCKET NO.: B0801.70256US01			
				FILING DATE: November 12, 2003		CONFIRMATION NO.: 8225			
				APPLICANT: Pier et al.					
				GROUP ART UNIT: 1645		EXAMINER: Not Yet Assigned			
Sheet	2	of	7						

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
	B2	EP	0 694 309	A2	Kitasato Institute	10-31-1996	
	B3	FR	2 410 043	A1	Yoshida	06-22-1979	Y – Abstr.
	B4	FR	2 581 877	A1	Universite Catholique de Louvain	11-21-1986	Y – Abstr.
	B5	FR	2 640 628	A1	Commissariat A L'Energie Atomique	12-16-1988	Y – Abstr.
	B6	GB	2 009 771	A	Yoshida	06-20-1979	
	B7	WO	85/05037	A1	Syntex, AB	11-21-1985	
	B8	WO	86/02358	A1	Technology License Company Limited	04-24-1986	
	B9	WO	88/02028	A1	Technology License Company Limited	03-24-1988	
	B10	WO	89/04873	A1	University of North Carolina	06-01-1989	
	B11	WO	90/03398	A1	Brigham and Women's Hospital	04-05-1990	
	B12	WO	90/06696	A2	Praxis Biologics, Inc.	06-28-1990	
	B13	WO	93/01276	A1	Smithkline Beecham Corporation	01-21-1993	
	B14	WO	93/09811	A1	Univax Biologics, Inc.	05-27-1993	
	B15	WO	93/19373	A1	Fischer	09-30-1993	
	B16	WO	94/15640	A1	Gristina	07-21-1994	
	B17	WO	98/52605	A1	Sumitomo Pharmaceuticals Company, Ltd	11-26-1998	
	B18	WO	00/35504	A1	SCA Hygiene Products Zeist B.V.	06-22-2000	
	B19	WO	00/03745	A2	Brigham and Women's Hospital	01-27-2000	
	B20	WO	2004/043405	A2	The Brigham and Women's Hospital, Inc.	05-27-2004	
	B21	WO	2004/043407	A2	The Brigham and Women's Hospital, Inc.	05-27-2004	

OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
	C5	GENBANK Submission; NIH/NCBI, Accession No. BA000018; Kuroda et al.; October 22, 2004 (last submission).		
	C6	[No Author Listed] ATCC Catalogue website 2001; ATCC Number 35984.		
	C7	[No Author Listed] ATCC Catalogue: Bacteria and Bacteriophages; 1992; 18th Edition; p301.		
	C8	AMMENDOLIA et al., Slime production and expression of the slime-associated antigen by staphylococcal clinical isolates. J Clin Microbiol. 1999 Oct;37(10):3235-8.		
	C9	BARSHAM et al., Detection of antibodies to Staphylococcus epidermidis in infected total hip replacements by an enzyme linked immunosorbent assay. J Clin Pathol. 1985 Jul;38(7):839-40.		
	C10	BERNSTEIN, et al., Antibody coated bacteria in otitis media with effusions. Ann Otol Rhinol Laryngol Suppl. 1980 May-Jun;89(3 Pt 2):104-9. Abstract only.		
	C11	CAPEK et al., Chapters 22: Carbohydrates and Chapter 23: Polysaccharides. in Journal of Chromatography Journal Library – Volume 3: Liquid Column Chromatography, A Survey of Modern Techniques and Applications. Deyl et al., eds. Elsevier Scientific Publishing Company: New York, 1975. p465-528.		
	C12	CHANTER, Partial purification and characterization of two non K99 mannose-resistant haemagglutinins of Escherichia coli B41. J Gen Microbiol. 1983 Jan;129(1):235-43.		

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/712,391		ATTY. DOCKET NO.: B0801.70256US01	
				FILING DATE: November 12, 2003		CONFIRMATION NO.: 8225	
				APPLICANT: Pier et al.			
				GROUP ART UNIT: 1645		EXAMINER: Not Yet Assigned	
Sheet	3	of	7				

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
	C13	CHEN et al., Characterization and biological properties of chemically deglycosylated human chorionic gonadotropin. Role of carbohydrate moieties in adenylate cyclase activation. J Biol Chem. 1982 Dec 10;257(23):14446-52.		
	C14	CHRISTENSEN et al., Adherence of slime-producing strains of Staphylococcus epidermidis to smooth surfaces. Infect Immun. 1982 Jul;37(1):318-26.		
	C15	CHU et al., Preparation, characterization, and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type 1 (Shiga's bacillus) bound to tetanus toxoid. Infect Immun. 1991 Dec;59(12):4450-8.		
	C16	CONLON et al., icaR encodes a transcriptional repressor involved in environmental regulation of ica operon expression and biofilm formation in Staphylococcus epidermidis. J Bacteriol. 2002 Aug;184(16):4400-8.		
	C17	CONLON et al., Regulation of icaR gene expression in Staphylococcus epidermidis. FEMS Microbiol Lett. 2002 Nov 5;216(2):171-7.		
	C18	CRAMTON et al., The intercellular adhesion (ica) locus is present in Staphylococcus aureus and is required for biofilm formation. Infect Immun. 1999 Oct;67(10):5427-33.		
	C19	DOBRIN, et al., The role of complement, immunoglobulin and bacterial antigen in coagulase-negative staphylococcal shunt nephritis. Am J Med. 1975 Nov;59(5):660-73. Abstract only.		
	C20	ELDER et al., Characterization of monoclonal antibodies specific for adhesion: isolation of an adhesin of Streptococcus sanguis FW213. Infect Immun. 1986 Nov;54(2):421-7.		
	C21	ESPERSEN, et al., Solid-phase radioimmunoassay for IgG antibodies to Staphylococcus epidermidis. Use in serious coagulase-negative staphylococcal infections. Arch Intern Med. 1987 Apr;147(4):689-93. Abstract only.		
	C22	ESPERSEN, et al., Enzyme-linked immunosorbent assay for detection of Staphylococcus epidermidis antibody in experimental S. epidermidis endocarditis. J Clin Microbiol. 1986 Feb;23(2):339-42.		
	C23	FATTOM et al., Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A. Infect Immun. 1990 Jul;58(7):2367-74.		
	C24	FATTOM et al., Effect of conjugation methodology, carrier protein, and adjuvants on the immune response to Staphylococcus aureus capsular polysaccharides. Vaccine. 1995 Oct;13(14):1288-93.		
	C25	FERREIROS et al., Purification and partial characterization of a K99-antigen associated adhesin in Escherichia coli (637 strain). Rev Esp Fisiol. 1983 Mar;39(1):45-50.		
	C26	FOURNIER et al., Purification and characterization of Staphylococcus aureus type 8 capsular polysaccharide. Infect Immun. 1984 Jul;45(1):87-93.		
	C27	GERKE et al., Characterization of the N-acetylglucosaminyltransferase activity involved in the biosynthesis of the Staphylococcus epidermidis polysaccharide intercellular adhesin. J Biol Chem. 1998 Jul 17;273(29):18586-93.		
	C28	GRAY et al., Effect of extracellular slime substance from Staphylococcus epidermidis on the human cellular immune response. Lancet. 1984 Feb 18;1(8373):365-7.		
	C29	HEILMANN et al., Molecular basis of intercellular adhesion in the biofilm-forming Staphylococcus epidermidis. Mol Microbiol. 1996 Jun;20(5):1083-91.		
	C30	HEILMANN et al., Characterization of Tn917 insertion mutants of Staphylococcus epidermidis affected in biofilm formation. Infect Immun. 1996 Jan;64(1):277-82.		
	C31	HOGT et al., Cell surface characteristics of coagulase-negative staphylococci and their adherence to fluorinated poly(ethylenepropylene). Infect Immun. 1986 Jan;51(1):294-301.		
	C32	ICHIMAN et al., The relationship of capsular-type of Staphylococcus epidermidis to virulence and induction of resistance in the mouse. J Appl Bacteriol. 1981 Oct;51(2):229-41.		

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/712,391		ATTY. DOCKET NO.: B0801.70256US01			
				FILING DATE: November 12, 2003		CONFIRMATION NO.: 8225			
				APPLICANT: Pier et al.					
				GROUP ART UNIT: 1645		EXAMINER: Not Yet Assigned			
Sheet	4	of	7						

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
	C33	ICHIMAN et al., Induction of resistance with heat-killed unencapsulated strains of Staphylococcus epidermidis against challenge with encapsulated strains of Staphylococcus epidermidis. Microbiol Immunol. 1989;33(4):277-86.		
	C34	ICHIMAN et al., Relation of human serum antibody against Staphylococcus epidermidis cell surface polysaccharide detected by enzyme-linked immunosorbent assay to passive protection in the mouse. J Appl Bacteriol. 1991 Aug;71(2):176-81.		
	C35	ICHIMAN et al., Specificity of monoclonal antibodies against an encapsulated strain of staphylococcus epidermids. in The Staphylococci, Zbl Bakt. 1991;Suppl 21:150-2.		
	C36	JEFFERSON et al., Identification of a 5-nucleotide sequence that controls expression of the ica locus in Staphylococcus aureus and characterization of the DNA-binding properties of IcaR. Mol Microbiol. 2003 May;48(4):889-99.		
	C37	JEFFERSON et al., The teicoplanin-associated locus regulator (TcaR) and the intercellular adhesin locus regulator (IcaR) are transcriptional inhibitors of the ica locus in Staphylococcus aureus. J Bacteriol. 2004 Apr;186(8):2449-56.		
	C38	JOHNSON et al., Interference with granulocyte function by Staphylococcus epidermidis slime. Infect Immun. 1986 Oct;54(1):13-20.		
	C39	KELLY-QUINTOS et al., Biological Characterization of Fully Human Monoclonal Antibodies to Staphylococcal Surface Polysaccharide PNAG. Abstracts of the 104th General Meeting of the American Society for Microbiology. Am Soc Microbiol. 2004 May;abstract A-63. Abstract and corresponding presentation.		
	C40	KEUTMANN et al., Evidence for a conformational change in deglycosylated glycoprotein hormones. FEBS Lett. 1985 Jun 17;185(2):333-8.		
	C41	KOHLER, Derivation and diversification of monoclonal antibodies. Science. 1986 Sep 19;233(4770):1281-6.		
	C42	KOJIMA et al., Antibody to the capsular polysaccharide/adhesin protects rabbits against catheter-related bacteremia due to coagulase-negative staphylococci. J Infect Dis. 1990 Aug;162(2):435-41.		
	C43	KURODA et al., Whole genome sequencing of meticillin-resistant Staphylococcus aureus. Lancet. 2001 Apr 21;357(9264):1225-40.		
	C44	LEE et al., Chemical characterization and immunogenicity of capsular polysaccharide isolated from mucoid Staphylococcus aureus. Infect Immun. 1987 Sep;55(9):2191-7.		
	C45	LEE et al., Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats. Infect Immun. 1997 Oct;65(10):4146-51.		
	C46	LEITH et al., Purification of a Mycoplasma pneumoniae adhesin by monoclonal antibody affinity chromatography. J Bacteriol. 1984 Feb;157(2):678-80.		
	C47	LOCKSLEY, Chapter 94: Staphylococcal Infections. in Harrison's Principles of Internal Medicine, Eleventh Edition. Braunwald et al., eds. McGraw-Hill Book Company, Inc.: New York, 1950. p537-43.		
	C48	LUDWICKA et al., Investigation on extracellular slime substance produced by Staphylococcus epidermidis. Zentralbl Bakteriell Mikrobiol Hyg [A]. 1984 Dec;258(2-3):256-67.		
	C49	MACK et al., Association of biofilm production of coagulase-negative staphylococci with expression of a specific polysaccharide intercellular adhesin. J Infect Dis. 1996 Oct;174(4):881-4.		
	C50	MACK et al., Characterization of transposon mutants of biofilm-producing Staphylococcus epidermidis impaired in the accumulative phase of biofilm production: genetic identification of a hexosamine-containing polysaccharide intercellular adhesin. Infect Immun. 1994 Aug;62(8):3244-53.		
	C51	MACK et al., Parallel induction by glucose of adherence and a polysaccharide antigen specific for plastic-adherent Staphylococcus epidermidis: evidence for functional relation to intercellular adhesion. Infect Immun. 1992 May;60(5):2048-57.		

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/712,391		ATTY. DOCKET NO.: B0801.70256US01	
				FILING DATE: November 12, 2003		CONFIRMATION NO.: 8225	
				APPLICANT: Pier et al.			
				GROUP ART UNIT: 1645		EXAMINER: Not Yet Assigned	
Sheet	5	of	7				

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C52	MACK et al., Essential functional role of the polysaccharide intercellular adhesin of Staphylococcus epidermidis in hemagglutination. Infect Immun. 1999 Feb;67(2):1004-8.	
	C53	MACK et al., Identification of three essential regulatory gene loci governing expression of Staphylococcus epidermidis polysaccharide intercellular adhesin and biofilm formation. Infect Immun. 2000 Jul;68(7):3799-807.	
	C54	MAIRA-LITRAN et al., Deacetylated-poly-N-acetyl Glucosamine (dPNAG) Polysaccharide Conjugated to Diphtheria Toxoid (DT) Confers Protection Against Multiple Strains of Staphylococcus aureus in a Murine Model of Bacteremia. Abstracts of the 104th General Meeting of the American Society for Microbiology. Am Soc Microbiol. 2004 May;abstract D-130. Abstract and corresponding presentation.	
	C55	MAIRA-LITRAN et al., Synthesis and Immunological Properties of a Staphylococcal Deacetylated-poly-N-acetyl Glucosamine (dPNAG) Polysaccharide and Clumping Factor A (ClfA) Protein Conjugate Vaccine. Abstracts of the 104th General Meeting of the American Society for Microbiology. Am Soc Microbiol. 2004 May;abstract E-062. Abstract and corresponding presentation.	
	C56	McKENNEY et al., Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. Science. 1999 May 28;284(5419):1523-7.	
	C57	McKENNEY et al., Vaccine potential of poly-1-6 beta-D-N-succinylglucosamine, an immunoprotective surface polysaccharide of Staphylococcus aureus and Staphylococcus epidermidis. J Biotechnol. 2000 Sep 29;83(1-2):37-44.	
	C58	MELEAN et al., Toward the automated solid-phase synthesis of oligoglucosamines: systematic evaluation of glycosyl phosphate and glycosyl trichloroacetimidate building blocks. Carbohydr Res. 2002 Nov 19;337(21-23):1893-916.	
	C59	MILSTEIN, From antibody structure to immunological diversification of immune response. Science. 1986 Mar 14;231(4743):1261-8.	
	C60	MOCH et al., Isolation and characterization of the alpha-sialyl-beta-2,3-galactosyl-specific adhesin from fimbriated Escherichia coli. Proc Natl Acad Sci U S A. 1987 May;84(10):3462-6.	
	C61	MOREAU et al., Structure of the type 5 capsular polysaccharide of Staphylococcus aureus. Carbohydr Res. 1990 Jul 1;201(2):285-97.	
	C62	MULLER et al., Occurrence of capsular polysaccharide/adhesin among clinical isolates of coagulase-negative staphylococci. J Infect Dis. 1993 Nov;168(5):1211-8.	
	C63	NAGY et al., Multi-adhesin vaccines for the protection of the neonatal piglet against "E. coli" infections. Dev Biol Stand. 1983;53:189-97.	
	C64	NAKANO, et al., Polyclonal antibody production in murine spleen cells induced by Staphylococcus. Microbiol Immunol. 1980;24(10):981-94. Abstract only.	
	C65	OHSHIMA et al., Cell surface antigen of encapsulated Staphylococcus epidermidis ATCC 31432. J Clin Microbiol. 1987 Jul;25(7):1338-40.	
	C66	OHSHIMA et al., Protection inducing antigen of an encapsulated staphylococcus epidermis SE-10. in The Staphylococci, Zbl Bakt. 1991;Suppl 21:279-80.	
	C67	ORSKOV et al., An adhesive protein capsule of Escherichia coli. Infect Immun. 1985 Jan;47(1):191-200.	
	C68	PETERS et al., Biology of s.epidermidis extracellular slime. in The Staphylococci, Zbl Bakt . 1987;Suppl 16:15-33.	
	C69	QUIE et al., Coagulase-negative staphylococcal adherence and persistence. J Infect Dis. 1987 Oct;156(4):543-7.	
	C70	ROGEMOND et al., Lectinlike adhesins in the Bacteroides fragilis group. Infect Immun. 1986 Jul;53(1):99-102.	

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/712,391	ATTY. DOCKET NO.: B0801.70256US01
				FILING DATE: November 12, 2003	CONFIRMATION NO.: 8225
				APPLICANT: Pier et al.	
				GROUP ART UNIT: 1645	EXAMINER: Not Yet Assigned
Sheet	6	of	7		

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C71	RUPP et al., Characterization of the importance of polysaccharide intercellular adhesin/hemagglutinin of Staphylococcus epidermidis in the pathogenesis of biomaterial-based infection in a mouse foreign body infection model. Infect Immun. 1999 May;67(5):2627-32.	
	C72	RUPP et al., Characterization of Staphylococcus epidermidis polysaccharide intercellular adhesin/hemagglutinin in the pathogenesis of intravascular catheter-associated infection in a rat model. Infect Immun. 1999 May;67(5):2656-9.	
	C73	SANFORD et al., Detection of staphylococcal membrane receptors on virus-infected cells by direct adhesin overlay. Infect Immun. 1986 Jun;52(3):671-5.	
	C74	SCHUMACHER-PERDREAU et al., Comparative analysis of a biofilm-forming Staphylococcus epidermidis strain and its adhesion-positive, accumulation-negative mutant M7. FEMS Microbiol Lett. 1994 Mar 15;117(1):71-8.	
	C75	SOMPOLINSKY et al., Encapsulation and capsular types in isolates of Staphylococcus aureus from different sources and relationship to phage types. J Clin Microbiol. 1985 Nov;22(5):828-34.	
	C76	TAKEDA et al., Protection against endocarditis due to Staphylococcus epidermidis by immunization with capsular polysaccharide/adhesin. Circulation. 1991 Dec;84(6):2539-46.	
	C77	THOMAS et al., Enzyme-linked lectinsorbent assay measures N-acetyl-D-glucosamine in matrix of biofilm produced by Staphylococcus epidermidis. Curr Microbiol. 1997 Oct;35(4):249-54.	
	C78	TOJO et al., Isolation and characterization of a capsular polysaccharide adhesin from Staphylococcus epidermidis. J Infect Dis. 1988 Apr;157(4):713-22.	
	C79	TOLLERSRUD et al., Genetic and serologic evaluation of capsule production by bovine mammary isolates of Staphylococcus aureus and other Staphylococcus spp. from Europe and the United States. J Clin Microbiol. 2000 Aug;38(8):2998-3003.	
	C80	VERSHIGORA et al., Secretory antibodies to homologous and heterologous staphylococcal strains in the colostrum of rabbits. Zh Mikrobiol Epidemiol Immunobiol. 1980;88-90. Russian.	Y – Abstr.
	C81	VUONG et al., A crucial role for exopolysaccharide modification in bacterial biofilm formation, immune evasion, and virulence. J Biol Chem. 2004 Dec 24;279(52):54881-6. Epub 2004 Oct 22.	
	C82	WANG et al., The pgaABCD locus of Escherichia coli promotes the synthesis of a polysaccharide adhesin required for biofilm formation. J Bacteriol. 2004 May;186(9):2724-34.	
	C83	WESSELS et al., Isolation and characterization of type IV group B Streptococcus capsular polysaccharide. Infect Immun. 1989 Apr;57(4):1089-94.	
	C84	WRAY et al., Identification and characterization of a uroepithelial cell adhesin from a uropathogenic isolate of Proteus mirabilis. Infect Immun. 1986 Oct;54(1):43-9.	
	C85	YAMADA, et al., Possible common biological and immunological properties for detecting encapsulated strains of Staphylococcus epidermidis. J Clin Microbiol. 1988 Oct;26(10):2167-72.	
	C86	YOSHIDA et al., Mouse virulent strain of Staphylococcus epidermidis. Relation of antiphagocytic activity to the protection-inducing antigen. Jpn J Microbiol. 1976 Jun;20(3):209-17.	
	C87	YOSHIDA, et al., Immunological response to a strain of Staphylococcus epidermidis in the rabbit: production of protective antibody. J Med Microbiol. 1978 Nov;11(4):371-7. Abstract only.	
	C88	YOSHIDA et al., Cross protection between a strain of Staphylococcus epidermidis and eight other species of coagulase-negative staphylococci. Can J Microbiol. 1988 Jul;34(7):913-5.	
	C89	YOUNG, Staphylococci, Staphylococcal Disease, and Toxic Shock Syndrome. in The Biologic and Clinical Basis of Infectious Diseases, Third Edition.. Youmans et al., eds. W.B. Saunders Company: Philadelphia, 1985. p 618-29 and 738-9.	
	C90	ZIEBUHR et al., Detection of the intercellular adhesion gene cluster (ica) and phase variation in Staphylococcus epidermidis blood culture strains and mucosal isolates. Infect Immun. 1997 Mar;65(3):890-6.	

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/712,391		ATTY. DOCKET NO.: B0801.70256US01			
				FILING DATE: November 12, 2003		CONFIRMATION NO.: 8225			
				APPLICANT: Pier et al.					
				GROUP ART UNIT: 1645		EXAMINER: Not Yet Assigned			
Sheet	7	of	7						

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C91	ZIEBUHR et al., A novel mechanism of phase variation of virulence in Staphylococcus epidermidis: evidence for control of the polysaccharide intercellular adhesin synthesis by alternating insertion and excision of the insertion sequence element IS256. Mol Microbiol. 1999 Apr;32(2):345-56.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an eIDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]